In addition to CIDP indication, the asset is also being assessed for inflammatory bowel disease, rheumatoid arthritis, and non-alcoholic steatohepatitis. Credit: PeopleImages.com – Yuri A/Shutterstock.

Kine Sciences has dosed the first subject in its Phase Ib/IIa clinical trial of KINE-101, a new nano peptide aimed at treating chronic inflammatory demyelinating polyneuropathy (CIDP).

KINE-101, which operates by activating Treg cells, is designed to modulate both humoral immunity and cell-mediated immune responses.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This development follows the successful completion of a Phase I study in October last year, which demonstrated an excellent safety profile for KINE-101.

The US Food and Drug Administration (FDA) granted clearance in September 2021 for the Phase I study, which involved 40 healthy participants across five cohorts over 42 days.

The trial included four cohorts receiving intravenous doses of KINE-101 ranging from 10mg to 300mg and one cohort receiving a 96.8mg subcutaneous dose.

See Also:

Apart from CIDP indication, the asset is also being assessed for other conditions such as inflammatory bowel disease, rheumatoid arthritis, and non-alcoholic steatohepatitis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Founded in 2016, Kine Sciences is focused on developing ultra-small peptides for immune-mediated diseases based on functional immunomics.

Its peptides stem from a new anti-inflammatory cytokine that targets various immune cells, offering potential benefits such as a favourable pharmacokinetic versus pharmacodynamic profile, reduced immunogenicity and antigenicity, production costs, and potential for oral dosing.

Kine Sciences CEO Dae Ho Cho said: “Dosing the first patient marks our first programme in the clinic and represents an important milestone for our company.

“We look forward to the clinical data that will support the strong efficacy that we have seen in the preclinical studies. KINE-101 has a unique mechanism of action that targets what we believe is an underlying cause of the disease and differentiates it from symptomatic treatments. Moving forward, KINE-101 has the potential to offer more effective treatment options for CIDP patients either as a standalone therapy or in combination with existing treatments.”